Lung cancer is the most commonly diagnosed cancer, accounting for the most cancer deaths each year. It is very hard to detect in its early stages and may take years to grow.
"I started out the day as a healthy, 52-year-old, non-smoker. But by the end of the day, a sudden seizure had landed me in the hospital and I was diagnosed with inoperable, Stage IV lung cancer that had spread to my brain. I consulted with Dr. Nagourney at his research laboratory, Rational Therapeutics. He examined me and then explained I wasn’t sick, I had cancer, and his goal was to keep me from getting sick.".
Lung cancer can form anywhere in the lung tissue, but more than 90 percent of these cancers are thought to arise in the epithelial cells which line the airways. The most common forms of this cancer are:
"One of the luckiest days of my life was when Dr. Nagourney agreed to meet with me. He explained the basis for his approach to treating cancer was to obtain a sample of the cancerous tissue and test a wide variety of chemo medicines against it. The chemo(s) that responded the best to eliminating the cancer were then to be used to battle it.".
Currently, oncologists base their treatment strategy on standard chemotherapy protocols for specific types of cancer. While lung cancer patients with EGFr or ALK mutations may be eligible for newer targeted therapies, those without mutations will be treated with one of several platinum doublets that combine cisplatin or carboplatin with vinorelbine, paclitaxel, gemcitabine, Docetaxel or pemetrexed. While small cell patients most often receive cisplatin plus etoposide or cisplatin plus irinotecan.
These protocols, developed over years of clinical trials, assign patients to the drugs for which they have the greatest statistical probability of response. Even with the standard expected response rate of 30 percent, that leaves 7 out of 10 patients receiving treatment without benefit.
An October 2012 study published in the journal of Anticancer Research revealed that metastatic lung cancer patients who received treatments chosen by the EVA-PCD functional profile realized a two-fold improvement in response and survival. The following article published by investigators at the National Cancer Institute, utilizing laboratory techniques developed and applied at Rational Therapeutics, correlates survival with the use of the “invitro best regimen” (IVBR). With a 39 percent durable complete remission rate for patients receiving assay “sensitive” therapy, this remains one of the best outcomes in this lethal disease ever reported.
Just like in the cases of, and the other lung cancer patients helped by our staff at Rational Therapeutics, let us help find the right treatment for you. Read their stories.